Testing the Addition of the Immunotherapy Drug, Pembrolizumab, to Radiation Therapy Compared to the Usual Chemotherapy Treatment During Radiation Therapy for Bladder Cancer, PARRC Trial
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Center, Korea
NRG Oncology
Mayo Clinic
Aarhus University Hospital
Janssen Research & Development, LLC
UroGen Pharma Ltd.
National Cancer Institute (NCI)
First Affiliated Hospital of Wenzhou Medical University
Hospital Centre Biel/Bienne
Merck Sharp & Dohme LLC
UroGen Pharma Ltd.
Radiation Therapy Oncology Group
UroGen Pharma Ltd.
UroGen Pharma Ltd.
University of Bern
University of Sydney
Corewell Health West
Mayo Clinic
UroGen Pharma Ltd.
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Viralytics
Halozyme Therapeutics
CG Oncology, Inc.
Medical Enterprises Ltd.
Institute of Cancer Research, United Kingdom
Azienda Ospedaliera "Sant'Andrea"
TC Erciyes University
Bioniche Life Sciences Inc.
UroGen Pharma Ltd.
The University of Texas Health Science Center at San Antonio
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
European Organisation for Research and Treatment of Cancer - EORTC
European Organisation for Research and Treatment of Cancer - EORTC
University of Rome Tor Vergata